Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr;73(4):272-274.
doi: 10.1007/s00101-024-01396-3. Epub 2024 Apr 3.

[What is new…for factor XI inhibitors: DOAC 2.0?]

[Article in German]
A Schlake  1 , P Scheiermann  2 , C F Weber  3   4
Affiliations
Editorial

[What is new…for factor XI inhibitors: DOAC 2.0?]

[Article in German]
A Schlake et al. Anaesthesiologie. 2024 Apr.
No abstract available

PubMed Disclaimer

References

    1. Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI. Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. J Am Coll Cardiol. 2021;78:625–631. doi: 10.1016/j.jacc.2021.06.010. - DOI - PMC - PubMed
    1. Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011;105:269–273. doi: 10.1160/TH10-05-0307. - DOI - PubMed
    1. Koulas I, Spyropoulos AC. A review of FXIa inhibition as a novel target for anticoagulation. Hamostaseologie. 2023;43:28–36. doi: 10.1055/a-1984-7021. - DOI - PubMed
    1. Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399:1383–1390. doi: 10.1016/S0140-6736(22)00456-1. - DOI - PubMed
    1. Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022;400:997–1007. doi: 10.1016/S0140-6736(22)01588-4. - DOI - PubMed

Publication types

LinkOut - more resources